We are developing a new class of therapeutics derived from sRNA-signatures

PIPELINE OF THERAPEUTIC PROGRAMS FOCUS ON AREAS WITH KNOWN HETEROGENEITY

Inflammation

Inflammation

Fibrosis

Fibrosis

Neurodegeneration

Neurodegeneration

ESTABLISHED ECOSYSTEM OF BIOTECH COMPANIES, RESEARCH ORGANIZATIONS, FOUNDATIONS AND ACADEMIC INSTITUTIONS

Academic collaborators

Drug developers

Technology providers

Want to learn more?

We have established a global network of collaborators across academia, industry and patient advocacy groups, who share our vision and commitment to patients.

Next: OUR PEOPLE MAKE OUR PLATFORM WORK